|
| |
|
|
|
| |
 |
 |
November 2009
Pharmaseed presents at the Israel Society for Neuroscience’s 18th annual meeting at the Princess Hotel, Eilat, Israel, November 22-24. Abstracts of the meeting were published in the Journal of Molecular Neuroscience (volume 39, supplement 1, November 2009).
June 2009
Pharmaseed participates in BioMed 2009 , the flagship Israeli life sciences industry conference, at Tel Aviv's David InterContinental Hotel June 15-17. The company attracted broad interest from potential clients in Europe and the U.S.
July 2008
Collaboration with MINDGENIX –Pharmaseed and MINDGENIX, a New York-based company specializing in pre-clinical neuroscience contract research services, agree that Pharmaseed will manage MINDGENIX’s third-party testing business, which involves the testing of compounds using APP/PS1 transgenic mice. Pharmaseed will operate all aspects of the testing business, including invoicing and collecting client payments, and MINDGENIX will be entitled to receive a portion of the revenue earned by Pharmaseed. The term of the agreement is three years and is renewable every year for five years.
May 2008
Pharmaseed exhibits at BioMed 2008, the largest annual event of the Israeli life science industry, held May 27- 29 at the David InterContinental Hotel in Tel Aviv.
June 2007
Pharmaseed exhibits at BioMed 2007, the largest annual event of the Israeli life science industry, held June 5-7 at the David InterContinental Hotel in Tel Aviv.
January 2007
Pharmaseed and Lannet, a U.S.-based pharma company specializing in the manufacturing and distribution of generic drugs, agree to collaborate on the development of a new generic compound.
December 2006
Pharmaseed presents at the annual meeting of the Israel Society for Neuroscience (ISFN).
May 2006
Pharmaseed exhibits at BioMed 2006, the largest annual event of the Israeli life science industry, held May 29-31 at Jerusalem's International Convention Center.
March 2006
Pharmaseed and the Canadian pharmaceutical company AlphaRx initiate a collaborative project for analyzing the potential use of AlphaRx molecules for the treatment of CNS disorders.
December 2005
Pharmaseed and MIGAL - Galilee Technology Center initiate a collaborative project to develop a new neuroprotectant compound.
December 2005
Pharmaseed and the Israel-based biopharmaceutical company Kernel BioPharma initiate a collaborative project to develop and commercialize a CNS functional genomics program.
|
|
|
|
|
| |
|
 |
|
 |
